Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Ligand Pharmaceuticals Incorporated develops drugs which regulate hormone activated intracellular receptors. These receptors play a role in regulating the genetic processes affecting diseases such as gynecological disorders and certain cancers, as well as cardiovascular, inflammatory, and skin diseases.
Website: ligand.com



Growth: Good revenue growth rate 121.2%, there is acceleration compared to average historical growth rates 11.7%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is positive, +1.6%. On average the margin is improving unsteadily. Gross margin is high, +78.5%. In the last quarter the company beat the estimated EPS, +156.2%. The company was ahead of estimated EPS in 100% of quarters (showing a gain of +$0.63 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -0.6% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 299.9% higher than minimum and 5.3% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 3.8x by EV / Sales multiple , the company can be 69.5% overvalued

Insiders: For the last 3 months insiders sold company shares on $0.6 mln (-0.019% of cap.)

Key Financials (Download financials)

Ticker: LGND
Share price, USD:  (0.0%)198.22
year average price 148.91  


year start price 115.19 2025-02-08

min close price 96.67 2025-04-08

max close price 209.29 2025-11-10

current price 198.22 2026-02-07
Common stocks: 16 861 299

Dividend Yield:  0.0%
FCF Yield LTM: -0.6%
EV / LTM EBITDA: 779.8x
EV / EBITDA annualized: 45.9x
Last revenue growth (y/y):  +121.2%
Last growth of EBITDA (y/y):  > +200.0%
Historical revenue growth:  +11.7%
Historical growth of EBITDA:  +13.2%
EV / Sales: 12.4x
Margin (EBITDA LTM / Revenue): 1.6%
Fundamental value created in LTM:
Market Cap ($m): 3 342
Net Debt ($m): -223
EV (Enterprise Value): 3 119
Price to Book: 3.5x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-12-10seekingalpha.com

Ligand Pharmaceuticals Incorporated (LGND) Analyst/Investor Day Transcript

2025-11-08seekingalpha.com

Ligand Pharmaceuticals Incorporated (LGND) Q3 2025 Earnings Call Transcript

2025-09-25globenewswire.com

Arecor announces Co-development Agreement with US Insulin Pump Device Company for AT278 & Sale of Royalty Rights and Technology Access Fees for AT220 and AT292

2025-08-11globenewswire.com

Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering

2025-08-07seekingalpha.com

Ligand Pharmaceuticals Incorporated (LGND) Q2 2025 Earnings Call Transcript

2025-07-02globenewswire.com

Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics

2025-06-24seekingalpha.com

Ligand Pharmaceuticals: Attractive Royalty Model Powers Forward

2025-04-17globenewswire.com

Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics

2025-02-27seekingalpha.com

Ligand Pharmaceuticals Incorporated (LGND) Q4 2024 Earnings Call Transcript

2025-02-03seekingalpha.com

Looking Back On Ligand Pharmaceuticals
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol LGND LGND LGND LGND LGND LGND LGND LGND LGND LGND LGND LGND LGND LGND
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 886 163 886 163 886 163 886 163 886 163 886 163 886 163 886 163 886 163 886 163 886 163 886 163 886 163 886 163
fillingDate 2025-11-07 2025-08-08 2024-11-08 2024-08-07 2024-05-08 2023-11-09 2023-08-09 2023-05-08 2022-11-08
acceptedDate 2025-11-07 16:04:41 2025-08-08 16:12:04 2025-02-28 16:02:16 2024-11-08 16:01:40 2024-08-07 16:30:54 2024-05-08 16:07:27 2024-02-29 16:16:14 2023-11-09 17:03:00 2023-08-09 16:03:44 2023-05-08 16:07:29 2023-02-28 16:03:40 2022-11-08 16:03:23 2022-02-28 17:27:37 2021-02-24 17:03:22
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 115M 48M 167M 52M 42M 31M 131M 33M 26M 44M 196M 66M 242M 164M
costOfRevenue 25M 3M 11M 12M 11M 11M 35M 3M 2M 4M 53M 14M 62M 30M
grossProfit 91M 45M 156M 39M 30M 20M 96M 29M 25M 40M 143M 52M 179M 133M
grossProfitRatio 0.785 0.939 0.759 0.731 0.643 0.894 0.937 0.915 0.786
researchAndDevelopmentExpenses 21M 7M 21M 6M 5M 6M 25M 6M 7M 7M 36M 22M 32M 41M
generalAndAdministrativeExpenses 28M 20M 79M 24M 18M 11M 53M 15M 11M 11M 70M 17M 47M 60M
sellingAndMarketingExpenses 0 0 0 0 2M 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 28M 20M 79M 24M 19M 11M 53M 15M 11M 11M 70M 17M 47M 60M
otherExpenses -14M 10M 79M 6M 2M -2M 7M -4M -873 000 9M 34M 12M -3M -5M
operatingExpenses 36M 36M 179M 36M 23M 17M 84M 28M 27M 26M 140M 51M 76M 96M
costAndExpenses 61M 39M 190M 49M 34M 28M 119M 32M 28M 30M 193M 65M 138M 126M
interestIncome 3M 2M 8M 1M 3M 2M 8M 2M 2M 1M 2M 259 000 886 000 8M
interestExpense 0 1M 3M 741 000 1M 141 000 656 000 -1000 2M 1M 2M 332 000 20M 27M
depreciationAndAmortization 8M 9M 35M 9M 9M 9M 37M 8M 9M -31M 43M 12M 51M 28M
ebitda 149M 21M 41M 3M -55M 12M 101M 23M 3M -17M 81M 13M 143M 57M
ebitdaratio 1.292 0.439 0.061 0.403 0.395 0.714 0.097 -0.382 0.202
operatingIncome 55M 8M -23M 3M 7M 3M 12M -122 000 -2M 14M 3M 2M 104M 38M
operatingIncomeRatio 0.476 0.177 0.061 0.178 0.096 -0.004 -0.075 0.323 0.024
totalOtherIncomeExpensesNet 86M 3M 25M -9M -46M 110M 52M -19M 3M 41M 33M -702 000 -32M -36M
incomeBeforeTax 141M 11M 3M -6M -65M 113M 64M -15M 3M 56M 36M 857 000 72M 1M
incomeBeforeTaxRatio 1.222 0.236 -0.122 -1.574 3.662 -0.467 0.12 1.263 0.013
incomeTaxExpense 24M 6M 7M 833 000 -13M 27M 10M -3M 881 000 12M 41M 453 000 -4M -5M
netIncome 117M 5M -4M -7M -52M 86M 52M -13M 2M 42M -33M 404 000 57M -3M
netIncomeRatio 1.016 0.102 -0.138 -1.25 2.781 -0.389 0.087 0.954 0.006
eps 5.99 0.25 -0.22 -0.39 -2.88 4.86 3.02 -0.74 0.13 2.46 -1.98 0.02 3.46 -0.18
epsdiluted 5.68 0.24 -0.39 -2.88 4.75 -0.74 0.13 2.33 0.02
weightedAverageShsOut 19M 19M 18M 18M 18M 18M 17M 17M 18M 17M 17M 17M 17M 16M
weightedAverageShsOutDil 20M 20M 18M 18M 18M 18M 18M 17M 18M 18M 17M 17M 17M 16M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-28 2024-02-29 2023-02-28 2022-02-28 2021-02-24
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 5M 7M 247 000 -19M -19M
ebit 6M 64M 38M 92M 29M
nonOperatingIncomeExcludingInterest -28M -52M -35M 12M 9M
netIncomeFromContinuingOperations -4M 54M -5M 76M 7M
netIncomeFromDiscontinuedOperations 0 -2M -28M -19M -10M
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -4M 52M -33M 57M -3M
epsDiluted -0.22 2.94 -1.98 3.34 -0.18

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol LGND LGND LGND LGND LGND LGND LGND LGND LGND LGND LGND LGND LGND LGND
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 886 163 886 163 886 163 886 163 886 163 886 163 886 163 886 163 886 163 886 163 886 163 886 163 886 163 886 163
fillingDate 2025-11-07 2025-08-08 2024-11-08 2024-08-07 2024-05-08 2023-11-09 2023-08-09 2023-05-08 2022-11-08
acceptedDate 2025-11-07 16:04:41 2025-08-08 16:12:04 2025-02-28 16:02:16 2024-11-08 16:01:40 2024-08-07 16:30:54 2024-05-08 16:07:27 2024-02-29 16:16:14 2023-11-09 17:03:00 2023-08-09 16:03:44 2023-05-08 16:07:29 2023-02-28 16:03:40 2022-11-08 16:03:23 2022-02-28 17:27:37 2021-02-24 17:03:22
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 139M 68M 72M 64M 18M 50M 23M 19M 219M 283M 45M 4M 20M 48M
shortTermInvestments 525M 188M 184M 156M 209M 261M 147M 171M 191M 194M 167M 117M 322M 364M
cashAndShortTermInvestments 665M 255M 256M 220M 227M 311M 170M 191M 219M 283M 212M 121M 341M 411M
netReceivables 58M 42M 42M 34M 37M 28M 39M 39M 28M 29M 35M 66M 92M 59M
inventory 12M 13M 14M 13M 21M 21M 24M 25M 27M 14M 13M 22M 27M 26M
otherCurrentAssets 19M 43M 17M 42M 31M 9M 3M 3M 3M 2M 2M 11M 5M 4M
totalCurrentAssets 754M 353M 332M 309M 312M 369M 237M 258M 277M 328M 264M 220M 465M 501M
propertyPlantEquipmentNet 11M 12M 25M 25M 25M 24M 25M 10M 15M 16M 27M 47M 33M 37M
goodwill 102M 102M 105M 105M 105M 105M 103M 419M 431M 440M 106M 698M 106M 190M
intangibleAssets 234M 250M 267M 275M 283M 291M 300M 7M 11M 10M 353M 10M 387M 606M
goodwillAndIntangibleAssets 335M 352M 372M 380M 388M 397M 403M 425M 442M 450M 458M 708M 492M 796M
longTermInvestments 42M 204M 11M 212M 48M 47M 112M 47M 0 0 3M 0 0 0
taxAssets 10M 829 000 72 000 78 000 190 000 51M 214 000 9M 9M 875 000 9M 36M 36M 24M
otherNonCurrentAssets 325M 27M 203M 28M 92M 26M 10M 21M 16M 16M 2M 40M 272M 4M
totalNonCurrentAssets 723M 596M 610M 645M 554M 545M 550M 511M 481M 483M 499M 830M 833M 862M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 1 477M 949M 942M 955M 866M 914M 787M 769M 758M 811M 763M 1 051M 1 298M 1 362M
accountPayables 28M 9M 5M 5M 2M 2M 2M 13M 17M 6M 5M 35M 8M 4M
shortTermDebt 2M 1M 0 1M 2M 1M 0 497 000 680 000 77M 77M 79M 0 0
taxPayables 0 1M 1M 2M 2M 1M 0 4M 11M 0 0 10M 0 0
deferredRevenue 135 000 732 000 2M 1M 1M 1M 2M 4M 11M 257 000 976 000 10M 654 000 29M
otherCurrentLiabilities 463 000 53M -3M 16M 11M 14M 5M 916 000 448 000 15M 6M 11M 23M 49M
totalCurrentLiabilities 31M 65M 37M 25M 19M 18M 17M 19M 29M 99M 99M 135M 42M 100M
longTermDebt 450M 5M 0 6M 6M 5M 0 6M 11M 11M 0 35M 321M 442M
deferredRevenueNonCurrent 0 0 0 0 3M 3M 15M 0 0 0 44 000 6M 0 0
deferredTaxLiabilitiesNonCurrent 23M 32M 33M 46M 30M 51M 32M 32M 28M 30M 31M 30M 31M 65M
otherNonCurrentLiabilities 23M 18M 36M 36M 33M 31M 17M 47M 25M 25M 25M -25M 81M 40M
totalNonCurrentLiabilities 496M 55M 74M 89M 73M 90M 70M 85M 64M 66M 66M 99M 435M 553M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 6M 6M 7M 7M 8M 5M 6M 6M 12M 12M 11M 2M 4M 14M
totalLiabilities 527M 120M 111M 114M 91M 107M 86M 104M 93M 165M 165M 234M 476M 653M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 20 000 20 000 20 000 19 000 19 000 18 000 18 000 18 000 17 000 17 000 17 000 17 000 17 000 16 000
retainedEarnings 578M 461M 499M 530M 537M 589M 503M 485M 495M 493M 451M 468M 449M 392M
accumulatedOtherComprehensiveIncomeLoss 9M 8M -6M 2M -935 000 -910 000 -817 000 -944 000 -967 000 -935 000 -984 000 -1M -917 000 -801 000
othertotalStockholdersEquity 363M 359M 309M 239M 218M 182M 171M 154M 349M
totalStockholdersEquity 950M 829M 830M 841M 775M 807M 701M 665M 665M 646M 597M 816M 821M 710M
totalEquity 950M 829M 830M 841M 775M 807M 701M 665M 665M 646M 597M 816M 821M 710M
totalLiabilitiesAndStockholdersEquity 1 477M 949M 955M 866M 914M 769M 758M 811M 1 051M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 1 477M 949M 942M 955M 866M 914M 787M 769M 758M 811M 763M 1 051M 1 298M 1 362M
totalInvestments 567M 392M 195M 368M 256M 307M 259M 204M 191M 194M 170M 117M 322M 364M
totalDebt 451M 6M 7M 7M 8M 6M 6M 6M 12M 89M 88M 79M 324M 456M
netDebt 312M -62M -65M -56M -11M -44M -17M -13M -207M -194M 43M 75M 305M 409M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-28 2024-02-29 2023-02-28 2022-02-28 2021-02-24
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 38M 33M 30M 85M 57M
otherReceivables 4M 6M 5M 6M 2M
prepaids 2M 1M 1M 0 0
totalPayables 12M 2M 5M 8M 4M
otherPayables 6M 0 0 0 0
accruedExpenses 26M 7M 9M 9M 9M
capitalLeaseObligationsCurrent 1M 410 000 715 000 1M 8M
capitalLeaseObligationsNonCurrent 6M 6M 10M 2M 6M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 337M 199M 148M 373M 318M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol LGND LGND LGND LGND LGND LGND LGND LGND LGND LGND LGND LGND LGND LGND
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 886 163 886 163 886 163 886 163 886 163 886 163 886 163 886 163 886 163 886 163 886 163 886 163 886 163 886 163
fillingDate 2025-11-07 2025-08-08 2024-11-08 2024-08-07 2024-05-08 2023-11-09 2023-08-09 2023-05-08 2022-11-08
acceptedDate 2025-11-07 16:04:41 2025-08-08 16:12:04 2025-02-28 16:02:16 2024-11-08 16:01:40 2024-08-07 16:30:54 2024-05-08 16:07:27 2024-02-29 16:16:14 2023-11-09 17:03:00 2023-08-09 16:03:44 2023-05-08 16:07:29 2023-02-28 16:03:40 2022-11-08 16:03:23 2022-02-28 17:27:37 2021-02-24 17:03:22
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome 117M 5M -4M -7M -52M 86M 52M -10M 2M 42M -33M 404 000 57M -3M
depreciationAndAmortization 7M 9M 35M 7M 9M 9M 37M 9M 9M 9M 51M 14M 51M 28M
deferredIncomeTax 9M -325 000 -16M -2M -21M 20M 12M 8M -10M 9M 21M -13M -9M -19M
stockBasedCompensation 15M 0 41M 26M 11M 7M 26M 7M 7M 6M 60M 13M 39M 31M
changeInWorkingCapital 11M -6M 19M -633 000 -8M 8M -34M -21M -5M 8M 66M 5M -52M -10M
accountsReceivables -16M -3M -6M 5M -9M 3M -3M -8M 1M 1M 55M -3M -29M -26M
inventory 4M -875 000 10M 2M 2M 3M -11M -611 000 -13M 2M 12M 962 000 -427 000 -18M
accountsPayables 1M -407 000 0 2M 2M -1M -5M -2M -5M -435 000 -3M 0 -1M -1M
otherWorkingCapital 4M -2M 16M -10M -3M 4M -16M -11M 11M 5M 2M 7M -22M 35M
otherNonCashItems -146M 9M 21M 13M 108M -91M -42M 15M -3M -40M -27M 2M -7M 28M
netCashProvidedByOperatingActivities 13M 16M 97M 37M 13M 19M 50M 8M -82 000 34M 138M 20M 79M 55M
investmentsInPropertyPlantAndEquipment -15 000 -214 000 -2M 4M -2M -105 000 -4M -487 000 -203 000 -2M -18M -5M -9M -4M
acquisitionsNet 0 0 -172M -96M -75M -998 000 -26M -26M 0 0 -750 000 0 494 000 -383M
purchasesOfInvestments -392M -63M -226M -5M -24M -78M -127M -18M -49M -40M -51M -580 000 -181M -423M
salesMaturitiesOfInvestments 53M 51M 270M 95M 47M 75M 194M 25M 57M 53M 234M 25M 221M 1 039M
otherInvestingActivites 4M 2M -44M -75M -501 000 136 000 83 000 130 000 47 000
netCashUsedForInvestingActivites -334M -11M -47M -55M -4M -20M 8M 11M 19M
debtRepayment 0 -7000 -10000 -4000 -5000 0 -77M -13 000 -38M
commonStockIssued -12M 8M -25M 10M 15M 8M 9M 0 0
commonStockRepurchased 0 0 0 0 0 -3M 0 -103 000 -32 000 0 -8M 0 -18M -78M
dividendsPaid 0 0 0 0 0 0 -9M 0 0
otherFinancingActivites -10M 7M 55M 9M -3M -4M 9M -762 000 -3M
netCashUsedProvidedByFinancingActivities -10M 15M 55M 10M 12M 3M -68M -775 000 -41M
effectOfForexChangesOnCash 0 -447 000 -1M 377 000 0 0 0 14M 70M 0 0 0 0 0
netChangeInCash -68M 20M 49M 45M -32M 27M -22M -9M -60M 44M 25M -1M -28M -24M
cashAtEndOfPeriod 0 68M 72M 64M 18M 50M 23M 20M 28M 89M 45M 4M 20M 48M
cashAtBeginningOfPeriod 68M 48M 23M 18M 50M 23M 45M 28M 89M 45M 20M 5M 48M 72M
operatingCashFlow 13M 16M 97M 37M 13M 19M 50M 8M -82 000 34M 138M 20M 79M 55M
capitalExpenditure -15 000 -214 000 -20M -14M -2M -105 000 -54M -487 000 -203 000 -2M -18M -5M -9M -4M
freeCashFlow 13M 16M 77M 22M 11M 19M -4M 7M -285 000 32M 120M 15M 70M 50M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-28 2024-02-29 2023-02-28 2022-02-28 2021-02-24
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities -13M -50M -868 000 -1M 3M
netCashProvidedByInvestingActivities -144M -12M 164M 31M 232M
netDebtIssuance -25 000 -77M -261M -146M -232M
longTermNetDebtIssuance -25 000 -77M -261M -165M -232M
shortTermNetDebtIssuance 0 0 0 19M 0
netStockIssuance 37M 0 -8M 15M -78M
netCommonStockIssuance 37M 0 -8M 15M -78M
commonStockIssuance 37M 0 0 34M 0
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 60M 17M -7M -7M -789 000
netCashProvidedByFinancingActivities 97M -60M -276M -138M -311M
incomeTaxesPaid 19M 9M 12M 4M 2M
interestPaid 263 000 288 000 1M 3M 4M

Earning call transcript

2025 q3
2025-11-08 ET (fiscal 2025 q3)
2025 q2
2025-08-07 ET (fiscal 2025 q2)
2025 q1
2025-05-08 ET (fiscal 2025 q1)
2024 q4
2025-02-27 ET (fiscal 2024 q4)
2024 q3
2024-11-08 ET (fiscal 2024 q3)
2024 q2
2024-08-06 ET (fiscal 2024 q2)
2024 q1
2024-05-07 ET (fiscal 2024 q1)
2023 q4
2024-02-27 ET (fiscal 2023 q4)
2023 q3
2023-11-08 ET (fiscal 2023 q3)
2023 q2
2023-08-08 ET (fiscal 2023 q2)
2023 q1
2023-05-04 ET (fiscal 2023 q1)
2022 q4
2023-02-22 ET (fiscal 2022 q4)
2022 q3
2022-11-07 ET (fiscal 2022 q3)
2022 q2
2022-08-08 ET (fiscal 2022 q2)
2022 q1
2022-05-04 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 8
2025-11-06 12:08 ET
Ligand Pharmaceuticals published news for 2025 q3
SEC form 8
2025-11-06 12:08 ET
Ligand Pharmaceuticals reported for 2025 q3
SEC form 10
2025-08-08 16:12 ET
Ligand Pharmaceuticals reported for 2025 q2
SEC form 8
2025-08-07 11:04 ET
Ligand Pharmaceuticals published news for 2025 q2
SEC form 8
2025-08-07 11:04 ET
Ligand Pharmaceuticals reported for 2025 q2
SEC form 8
2025-07-02 11:10 ET
Ligand Pharmaceuticals published news for 2025 q2
SEC form 8
2025-07-02 11:10 ET
Ligand Pharmaceuticals published news for 2025 q2
SEC form 10
2025-05-09 20:04 ET
Ligand Pharmaceuticals published news for 2025 q1
SEC form 10
2025-05-09 00:00 ET
Ligand Pharmaceuticals published news for 2025 q1
SEC form 8
2025-05-08 11:06 ET
Ligand Pharmaceuticals published news for 2025 q1
SEC form 8
2025-05-08 11:06 ET
Ligand Pharmaceuticals reported for 2025 q1
SEC form 8
2025-04-17 10:08 ET
Ligand Pharmaceuticals published news for 2025 q1
SEC form 8
2025-04-17 10:08 ET
Ligand Pharmaceuticals published news for 2025 q1
SEC form 10
2025-02-28 21:02 ET
Ligand Pharmaceuticals published news for 2024 q4
SEC form 10
2025-02-28 00:00 ET
Ligand Pharmaceuticals published news for 2024 q4
SEC form 8
2025-02-27 07:06 ET
Ligand Pharmaceuticals published news for 2024 q4
SEC form 8
2025-02-27 07:06 ET
Ligand Pharmaceuticals reported for 2024 q4
SEC form 8
2025-02-25 21:02 ET
Ligand Pharmaceuticals published news for 2024 q4
SEC form 8
2025-02-25 21:02 ET
Ligand Pharmaceuticals published news for 2024 q4
SEC form 10
2024-11-08 16:01 ET
Ligand Pharmaceuticals published news for 2024 q3
SEC form 8
2024-11-07 07:11 ET
Ligand Pharmaceuticals published news for 2024 q3
SEC form 8
2024-11-07 07:11 ET
Ligand Pharmaceuticals published news for 2024 q3
SEC form 10
2024-08-07 16:30 ET
Ligand Pharmaceuticals published news for 2024 q2
SEC form 10
2024-08-07 00:00 ET
Ligand Pharmaceuticals published news for 2024 q2
SEC form 8
2024-08-06 16:08 ET
Ligand Pharmaceuticals published news for 2024 q2
SEC form 8
2024-08-06 16:08 ET
Ligand Pharmaceuticals reported for 2024 q2
SEC form 10
2024-05-08 00:00 ET
Ligand Pharmaceuticals published news for 2024 q1
SEC form 8
2024-05-07 16:03 ET
Ligand Pharmaceuticals published news for 2024 q1
SEC form 8
2024-05-07 16:03 ET
Ligand Pharmaceuticals reported for 2024 q1
SEC form 10
2024-02-29 00:00 ET
Ligand Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-27 07:24 ET
Ligand Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-27 07:24 ET
Ligand Pharmaceuticals reported for 2023 q4
SEC form 10
2023-11-09 00:00 ET
Ligand Pharmaceuticals published news for 2023 q3
SEC form 8
2023-11-08 16:08 ET
Ligand Pharmaceuticals reported for 2023 q3
SEC form 10
2023-08-09 16:03 ET
Ligand Pharmaceuticals published news for 2023 q2
SEC form 10
2023-08-09 00:00 ET
Ligand Pharmaceuticals published news for 2023 q2
SEC form 6
2023-08-08 16:02 ET
Ligand Pharmaceuticals reported for 2023 q2
SEC form 8
2023-08-08 00:00 ET
Ligand Pharmaceuticals published news for 2023 q2
SEC form 6
2023-06-09 17:00 ET
Ligand Pharmaceuticals published news for 2023 q1
SEC form 10
2023-05-08 00:00 ET
Ligand Pharmaceuticals published news for 2023 q1
SEC form 8
2023-05-04 00:00 ET
Ligand Pharmaceuticals published news for 2023 q1
SEC form 6
2023-03-13 08:02 ET
Ligand Pharmaceuticals published news for 2022 q4
SEC form 10
2023-02-28 16:03 ET
Ligand Pharmaceuticals reported for 2022 q4
SEC form 10
2023-02-28 00:00 ET
Ligand Pharmaceuticals reported for 2022 q4
SEC form 6
2023-02-22 16:05 ET
Ligand Pharmaceuticals published news for 2022 q4
SEC form 8
2023-02-22 00:00 ET
Ligand Pharmaceuticals reported for 2022 q4
SEC form 6
2022-12-27 18:31 ET
Ligand Pharmaceuticals published news for 2022 q3
SEC form 6
2022-12-27 18:31 ET
Ligand Pharmaceuticals published news for 2022 q3
SEC form 6
2022-12-27 18:30 ET
Ligand Pharmaceuticals published news for 2022 q3
SEC form 6
2022-12-27 18:28 ET
Ligand Pharmaceuticals published news for 2022 q3
SEC form 6
2022-12-27 18:26 ET
Ligand Pharmaceuticals published news for 2022 q3
SEC form 6
2022-12-27 18:26 ET
Ligand Pharmaceuticals published news for 2022 q3
SEC form 6
2022-12-14 16:07 ET
Ligand Pharmaceuticals published news for 2022 q3
SEC form 6
2022-12-05 07:03 ET
Ligand Pharmaceuticals published news for 2022 q3
SEC form 10
2022-11-08 16:03 ET
Ligand Pharmaceuticals reported for 2022 q3
SEC form 10
2022-11-08 00:00 ET
Ligand Pharmaceuticals reported for 2022 q3
SEC form 6
2022-11-07 20:26 ET
Ligand Pharmaceuticals published news for 2022 q3
SEC form 6
2022-11-07 20:23 ET
Ligand Pharmaceuticals published news for 2022 q3
SEC form 6
2022-11-07 16:04 ET
Ligand Pharmaceuticals published news for 2022 q3
SEC form 8
2022-11-07 00:00 ET
Ligand Pharmaceuticals reported for 2022 q3
SEC form 6
2022-11-04 16:08 ET
Ligand Pharmaceuticals published news for 2022 q3
SEC form 6
2022-11-03 21:10 ET
Ligand Pharmaceuticals published news for 2022 q3
SEC form 6
2022-11-03 21:05 ET
Ligand Pharmaceuticals published news for 2022 q3
SEC form 6
2022-10-03 09:18 ET
Ligand Pharmaceuticals published news for 2022 q3
SEC form 6
2022-09-30 17:13 ET
Ligand Pharmaceuticals published news for 2022 q2
SEC form 10
2022-08-09 16:13 ET
Ligand Pharmaceuticals reported for 2022 q2
SEC form 10
2022-08-09 00:00 ET
Ligand Pharmaceuticals reported for 2022 q2
SEC form 6
2022-08-08 16:06 ET
Ligand Pharmaceuticals published news for 2022 q2
SEC form 8
2022-08-08 00:00 ET
Ligand Pharmaceuticals reported for 2022 q2
SEC form 6
2022-08-02 16:10 ET
Ligand Pharmaceuticals published news for 2022 q2
SEC form 6
2022-06-29 17:17 ET
Ligand Pharmaceuticals published news for 2022 q1
SEC form 6
2022-06-21 06:19 ET
Ligand Pharmaceuticals published news for 2022 q1
SEC form 6
2022-06-10 19:26 ET
Ligand Pharmaceuticals published news for 2022 q1
SEC form 10
2022-05-09 16:08 ET
Ligand Pharmaceuticals reported for 2022 q1
SEC form 10
2022-05-09 00:00 ET
Ligand Pharmaceuticals reported for 2022 q1
SEC form 6
2022-05-04 16:03 ET
Ligand Pharmaceuticals published news for 2022 q1
SEC form 8
2022-05-04 00:00 ET
Ligand Pharmaceuticals reported for 2022 q1
SEC form 6
2022-04-22 16:11 ET
Ligand Pharmaceuticals published news for 2022 q1
SEC form 6
2022-03-24 09:08 ET
Ligand Pharmaceuticals published news for 2021 q4
SEC form 6
2022-03-23 17:25 ET
Ligand Pharmaceuticals published news for 2021 q4
SEC form 10
2022-02-28 17:27 ET
Ligand Pharmaceuticals published news for 2021 q4
SEC form 10
2022-02-28 00:00 ET
Ligand Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-17 16:03 ET
Ligand Pharmaceuticals published news for 2021 q4
SEC form 8
2022-02-17 00:00 ET
Ligand Pharmaceuticals published news for 2021 q4
SEC form 6
2022-01-27 16:02 ET
Ligand Pharmaceuticals published news for 2021 q4
SEC form 6
2022-01-14 16:23 ET
Ligand Pharmaceuticals published news for 2021 q4
SEC form 10
2021-11-09 17:06 ET
Ligand Pharmaceuticals published news for 2021 q3
SEC form 6
2021-11-09 16:06 ET
Ligand Pharmaceuticals published news for 2021 q3
SEC form 10
2021-11-09 00:00 ET
Ligand Pharmaceuticals published news for 2021 q3
SEC form 8
2021-11-09 00:00 ET
Ligand Pharmaceuticals published news for 2021 q3
SEC form 6
2021-08-16 16:15 ET
Ligand Pharmaceuticals published news for 2021 q2
SEC form 10
2021-08-03 00:00 ET
Ligand Pharmaceuticals published news for 2021 q2
SEC form 10
2021-08-02 19:56 ET
Ligand Pharmaceuticals published news for 2021 q2
SEC form 6
2021-07-29 16:04 ET
Ligand Pharmaceuticals published news for 2021 q2
SEC form 8
2021-07-29 00:00 ET
Ligand Pharmaceuticals published news for 2021 q2
SEC form 6
2021-07-21 09:05 ET
Ligand Pharmaceuticals published news for 2021 q2
SEC form 6
2021-07-14 16:08 ET
Ligand Pharmaceuticals published news for 2021 q2
SEC form 6
2021-06-04 19:48 ET
Ligand Pharmaceuticals published news for 2021 q1
SEC form 10
2021-05-06 16:07 ET
Ligand Pharmaceuticals published news for 2021 q1
SEC form 10
2021-05-06 00:00 ET
Ligand Pharmaceuticals published news for 2021 q1
SEC form 6
2021-05-03 16:11 ET
Ligand Pharmaceuticals published news for 2021 q1
SEC form 8
2021-05-03 00:00 ET
Ligand Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-23 16:09 ET
Ligand Pharmaceuticals published news for 2021 q1
SEC form 10
2021-02-24 17:03 ET
Ligand Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-03 07:45 ET
Ligand Pharmaceuticals published news for 2020 q4
SEC form 6
2021-01-28 16:42 ET
Ligand Pharmaceuticals published news for 2020 q4
SEC form 6
2020-12-21 08:39 ET
Ligand Pharmaceuticals published news for 2020 q3
SEC form 6
2020-12-16 16:19 ET
Ligand Pharmaceuticals published news for 2020 q3
SEC form 6
2020-12-10 16:13 ET
Ligand Pharmaceuticals published news for 2020 q3
SEC form 6
2020-12-02 20:05 ET
Ligand Pharmaceuticals published news for 2020 q3
SEC form 6
2020-11-23 08:32 ET
Ligand Pharmaceuticals published news for 2020 q3
SEC form 6
2020-11-12 16:16 ET
Ligand Pharmaceuticals published news for 2020 q3
SEC form 10
2020-11-06 16:11 ET
Ligand Pharmaceuticals published news for 2020 q3
SEC form 6
2020-10-30 17:01 ET
Ligand Pharmaceuticals published news for 2020 q3
SEC form 6
2020-10-30 16:07 ET
Ligand Pharmaceuticals published news for 2020 q3
SEC form 6
2020-10-30 08:03 ET
Ligand Pharmaceuticals published news for 2020 q3
SEC form 6
2020-10-20 10:52 ET
Ligand Pharmaceuticals published news for 2020 q3
SEC form 6
2020-10-13 08:44 ET
Ligand Pharmaceuticals published news for 2020 q3
SEC form 6
2020-10-01 08:42 ET
Ligand Pharmaceuticals published news for 2020 q3